TP53 and prostate carcinoma: Compared to wild-type p53 cells, prostate cancer cells expressing mutant p53 demonstrated reduced sensitivity in response to docetaxel, indicating that functional p53 is essential for sensitivity to docetaxel in prostate cancer cells 82,83.